Recro Pharma Inc (REPH) 9.70 $REPH Recro Pharma Reports

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Recro Pharma Inc (REPH) 9.70 $REPH

Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
GlobeNewswire - Tue Jul 26, 3:08PM CDT
IV Meloxicam Achieves Primary Endpoint in First of Two Pivotal Trials
REPH: 9.70 (-0.21)

Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid products for the treatment of serious acute pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on Thursday, June 9, 2016 at 11:00 am EDT. The conference is being held at the Grand Hyatt in New York City.
REPH: 9.70 (-0.21)

Recro Pharma reports 1Q loss
Automated Insights - Thu May 12, 8:16AM CDT
MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Thursday reported a loss of $6.5 million in its first quarter.
REPH: 9.70 (-0.21)

Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Thu May 12, 8:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing non-opioid products for the treatment of serious acute pain, today announced a poster presentation at the American Pain Society's 35 Annual Scientific Meeting, taking place May 11-14, 2016, in Austin, TX. The poster presentation highlights data from a clinical trial evaluating the efficacy and safety of intravenous (IV) meloxicam (N1539), in subjects with moderate to severe pain following open abdominal hysterectomy.
REPH: 9.70 (-0.21)

Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.31 (+0.03), REPH: 9.70 (-0.21)

Recro Pharma Reports Year End 2015 Financial Results
GlobeNewswire - Thu Mar 24, 7:20AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of serious acute pain, today reported financial results for the year ended December 31, 2015.
REPH: 9.70 (-0.21)

Recro Pharma to Present at the 28th Annual ROTH Conference
GlobeNewswire - Mon Mar 07, 7:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 28 Annual ROTH Conference on Monday, March 14, 2016 at 5:30 pm PST. The conference is being held at the Ritz Carlton Hotel in Dana Point, CA.
REPH: 9.70 (-0.21)

Recro Pharma to Present at NobleCon12 Investor Conference
GlobeNewswire - Thu Jan 14, 12:19PM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at Noble Financial Capital Markets' 12th Annual Investor Conference (NobleCon12) on Tuesday, January 19, 2016 at 4:00 pm EST. The conference is being held at Club Med in Sandpiper Bay, Florida.
REPH: 9.70 (-0.21)

Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 3.48 (-0.15), KMPH: 4.31 (+0.09), NKTR: 17.76 (+0.47), INSY: 15.91 (+0.26), AVXL: 3.61 (-0.23), PCRX: 37.58 (+1.33), REPH: 9.70 (-0.21), PTIE: 2.69 (-0.01)

The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
AMZN: 767.74 (+8.93), EFOI: 5.76 (-0.34), EGRX: 46.57 (+3.43), REPH: 9.70 (-0.21), NVDA: 56.73 (-0.37)

Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
GlobeNewswire - Wed Jan 06, 6:00AM CST
IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported
REPH: 9.70 (-0.21)

Buffett Fans Take Note: 5 Stocks That Crushed Berkshire Hathaway in 2015
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:23PM CST
There is no doubt that Berkshire Hathaway Inc. (BRK.B) is a stock that most investors want in their portfolio.
AMZN: 767.74 (+8.93), EFOI: 5.76 (-0.34), AXP: 64.13 (-0.33), IBM: 161.45 (+0.83), EGRX: 46.57 (+3.43), BRK.B: 143.93 (-0.34), REPH: 9.70 (-0.21), NVDA: 56.73 (-0.37)

5 Small Cap ETFs & Stocks that Beat Russell 2000 in 2015
Sweta Killa - Zacks Investment Research - Mon Jan 04, 9:59AM CST
These ETFs and stocks have shown strong resilience to the sharp downturn in the small cap space and the trend is likely to continue, making these lucrative picks for 2016.
PSCH: 74.90 (+0.31), NPTN: 12.60 (+0.05), LPTH: 1.89 (+0.05), REPH: 9.70 (-0.21), PSCT: 59.65 (+0.37), PSCU: 49.10 (-0.09)

The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
EFOI: 5.76 (-0.34), LPTH: 1.89 (+0.05), EGRX: 46.57 (+3.43), REPH: 9.70 (-0.21), HQCL: 13.66 (+0.26)

Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
GlobeNewswire - Wed Dec 02, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced the appointment of Stewart McCallum, M.D., as Chief Medical Officer.
REPH: 9.70 (-0.21)

Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 24, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 2015 Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 9:10 am EST. The conference is being held at the Lotte New York Palace Hotel in New York City.
REPH: 9.70 (-0.21)

Recro Pharma Reports Third Quarter 2015 Financial Results
GlobeNewswire - Fri Nov 13, 5:59AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today reported financial results for the third quarter ended September 30, 2015.
REPH: 9.70 (-0.21)

Recro Pharma to Participate in Upcoming Investor Conferences
GlobeNewswire - Thu Nov 12, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will participate in the following upcoming investor conferences:
REPH: 9.70 (-0.21)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVRx Lawsuit Deadline Follows a Brutal 59.76% Plunge

Updated Category News Views 160

A 59.76% one-day wipeout has a way of stripping the varnish off every upbeat corporate story. For CVRx investors, the hard fact is that the shares fell $3.55 to close at $2.39 on August 7, 2026, after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That kind of disclosure does not merely dent confidence; it forces...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 130

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 48

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 63

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 84

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 113

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 98

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Vusion's 2030 Plan Puts Recurring Revenue First At Scale

Updated Category News Views 77

Shelf labels are not exactly romance, yet Vusion has turned them into a serious growth machine. The 2030 plan is not really about hanging more electronic displays in aisles; it is about making those displays, sensors and store connections produce software and service revenue for years. That is the part of this story worth watching. The Hardware Base Is Becoming the Hook...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 92

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading

Top 5 Most Recently Viewed Articles

China's Investment Landscape Transformed by Market Reforms

Updated Category News Views 451

China's Market Value Reforms Enhancing Investment Confidence Recent developments in China’s market management are poised to reshape the landscape of investment, significantly boosting investor confidence. UBS analysts emphasize that these new measures represent a critical shift, aiming to cultivate a healthier environment for both domestic and foreign investors. Key...

Continue Reading
CI Financial Sees Significant Growth with Total Assets of $525B

Updated Category News Views 134

CI Financial Achieves Impressive Total Assets for October CI Financial Corp. (“CI”) (TSX: CIX) has recently announced a remarkable total asset figure of $525.3 billion. This impressive number celebrates a multifaceted asset landscape, including asset management assets totaling $136.1 billion, Canadian wealth management assets of $100.4 billion, Canadian custody assets...

Continue Reading
Carlyle Credit Income Fund Plans Second Quarter Results Update

Updated Category News Views 193

Carlyle Credit Income Fund Plans Second Quarter Results Update The Carlyle Credit Income Fund, often referred to as CCIF, has exciting news. The Fund is set to unveil its financial performance for the second quarter following market close on a specific upcoming Tuesday in May. This announcement represents a crucial moment for stakeholders and potential investors eager to...

Continue Reading
Lithia Motors Boosts Earnings: Price Target Climbs Significantly

Updated Category News Views 75

Lithia Motors Sees Price Target Hike After Strong Earnings Recently, Lithia Motors (NYSE: LAD) garnered attention in the financial markets as Stephens, a prominent financial services company, announced an increase in its price target for the automaker. The target officially rose from $360 to $405. This update follows a robust earnings report for the third quarter,...

Continue Reading
VFC Corporation Achieves 52-Week High: What it Means for Investors

Updated Category News Views 95

VFC Corporation Achieves New Market Heights In a remarkable surge, VFC Corporation's stock has reached a significant milestone by hitting a 52-week high at $20.7. This impressive figure is a clear indication of a substantial turnaround, demonstrating a remarkable 23.84% increase over the last year. Confidence among investors has rebounded as they recognize the apparel...

Continue Reading